<DOC>
	<DOCNO>NCT00094029</DOCNO>
	<brief_summary>The purpose study permit access SU011248 treatment use patient GIST give follow condition : ) patient undergo screening , eligible participation ongoing clinical study A6181004 ; AND b ) patient GIST standard treatment able control acceptable toxicity AND c ) patient potential derive clinical benefit treatment SU011248 .</brief_summary>
	<brief_title>A Treatment Protocol Patients With Gastrointestinal Stromal Tumor ( GIST ) Who May Derive Benefit From Treatment With SU011248</brief_title>
	<detailed_description>Given Expanded Access study meet definition control clinical investigation , , consider applicable drug clinical trial per NIH , Basic Results study require report . Protocol A6181036 identify Expanded Access trial , register ClinicalTrials.gov , however Basic Results post .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically proven Gastrointestinal Stomal Tumor ( GIST ) amenable standard therapy Undergone screening find ineligible participation ongoing SU011248 clinical study Patient judge potential derive clinical benefit SU011248 treatment treat physician Failed prior treatment imatinib mesylate , define either progression disease significant toxicity treatment imatinib mesylate preclude treatment Male Female , 18 year old Resolution acute toxicity prior therapy Adequate organ function Symptomatic congestive heart failure , myocardial infarction , coronary artery bypass graft last 6 month , ongoing severe unstable angina unstable arrhythmia require medication Symptomatic central nervous system metastases Serious acute chronic illness Current treatment another clinical trial Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>